Nocion to detail ASPIRE cough trial status as Q3 readout nears
A July 16 poster update on taplucainium precedes topline data from the placebo-controlled Phase 2b trial, the first U.S. cough therapy readout to test a charged sodium channel blocker.
Executive Summary
- Nocion Therapeutics will give a public status update on its lead cough trial days before the study's topline result is expected, in a disease with no new approved therapy in decades.
- Taplucainium works through a different route into airway nerve fibers than the P2X3-blocking drugs furthest along in this indication, a distinction the trial's placebo-controlled design is built to test.
- The trial's timeline slipped by months and enrollment grew to reach its final target before recruitment closed, but the study still finished enrollment cleanly and moved to its post-enrollment phase on schedule for a near-term readout.
- The nearest comparators in this exact patient population are already in Phase 3, so the pending result will be read against a mechanism class ahead of it in development, not against an unproven field.
The presentation
Nocion Therapeutics, Inc. will present a poster titled "The Nocion ASPIRE Study of Taplucainium in rCC: A Status Update" at the ERS 2026 Cough Conference in London on July 16, presented by Matthew Frankel, M.D.. The poster covers NCT06504446, the Phase 2b ASPIRE trial testing taplucainium inhalation powder in adults with refractory or unexplained chronic cough. Nocion has separately stated it is on track to report topline ASPIRE data in the third quarter of 2026. Nocion+1Nocion Therapeutics Announces Upcoming Poster Presentation at the ERS Cough Conference 2026Jul 7, 2026Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic CoughNCT06504446
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial tests
ASPIRE is a randomized, placebo-controlled study with three experimental arms and one placebo arm, enrolling 455 adults across the United States, Canada, Germany, Poland, the United Kingdom, and Belgium. The primary endpoint is change in 24-hour coughs per hour from baseline, measured against six secondary endpoints including the Leicester Cough Questionnaire and patient-reported impression of improvement. Taplucainium, formerly NTX-1175, is delivered once daily by inhalation and is designed as a charged sodium channel blocker intended to silence activated airway sensory nerves rather than target a single receptor, the mechanism used by rival P2X3 antagonists. NCT06504446+1Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic CoughNCT06504446Nocion Therapeutics Announces Upcoming Poster Presentation at the ERS Cough Conference 2026Jul 7, 2026
Timeline and enrollment
The trial's primary completion date moved from November 10, 2025 to April 10, 2026, and then to June 15, 2026, a cumulative slip of roughly seven months since the original registry estimate. Enrollment targets rose from 240 to 325 and then to 455 as the trial progressed, before recruitment closed and the study moved to Active, not recruiting status on June 11, 2026. The trial reached its final 455-patient target with no change to that number since August 2025, a routine outcome for a study that has finished enrolling. NCT06504446Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic CoughNCT06504446
The competitive field
No new therapy has been approved for chronic cough in the United States in 65 years, and the roughly 9 million adults with refractory or unexplained chronic cough are treated largely with off-label approaches. The nearest comparators sharing this exact patient population, GlaxoSmithKline's camlipixant and Merck's gefapixant, are P2X3 receptor antagonists already in Phase 3 testing, ahead of taplucainium in development stage. Taplucainium's charged sodium channel blocker class has not previously produced a resolved same-mechanism Phase 3 result in this population, so the ASPIRE readout will be the first test of whether this broader nerve-silencing approach can compete with the P2X3 mechanism already advancing toward later-stage trials. NocionNocion Therapeutics Announces Upcoming Poster Presentation at the ERS Cough Conference 2026Jul 7, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.